Aardvark Therapeutics Files 8-K
Ticker: AARD · Form: 8-K · Filed: Oct 9, 2025 · CIK: 1774857
| Field | Detail |
|---|---|
| Company | Aardvark Therapeutics, INC. (AARD) |
| Form Type | 8-K |
| Filed Date | Oct 9, 2025 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.00001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-k, filing, regulatory
TL;DR
Aardvark Therapeutics filed an 8-K on Oct 9th for an Oct 8th event. Details pending.
AI Summary
Aardvark Therapeutics, Inc. filed an 8-K on October 9, 2025, reporting an event on October 8, 2025. The filing indicates "Other Events" and "Financial Statements and Exhibits" as key items. The company is incorporated in Delaware and headquartered in San Diego, California.
Why It Matters
This 8-K filing signals a material event or update from Aardvark Therapeutics, Inc. that may impact investors and stakeholders.
Risk Assessment
Risk Level: low — The filing is a standard 8-K current report, not indicating immediate financial distress or significant negative news.
Key Numbers
- 001-42513 — SEC File Number (Identifies the company's filing history with the SEC.)
- 821606367 — IRS Employer Identification No. (Company's tax identification number.)
Key Players & Entities
- Aardvark Therapeutics, Inc. (company) — Registrant
- October 08, 2025 (date) — Date of earliest event reported
- October 9, 2025 (date) — Filing date
- San Diego, California (location) — Principal Executive Offices
FAQ
What specific 'Other Events' are being reported by Aardvark Therapeutics, Inc.?
The provided text does not detail the specific 'Other Events' beyond listing the item category.
What financial statements or exhibits are included in this 8-K filing?
The filing indicates 'Financial Statements and Exhibits' are included, but the specific documents are not detailed in the provided text.
When was the earliest event reported in this 8-K filing?
The earliest event reported was on October 08, 2025.
What is the principal executive office address for Aardvark Therapeutics, Inc.?
The principal executive offices are located at 4370 La Jolla Village Drive, Suite 1050, San Diego, California, 92122.
What is the SEC file number for Aardvark Therapeutics, Inc.?
The SEC file number for Aardvark Therapeutics, Inc. is 001-42513.
Filing Stats: 473 words · 2 min read · ~2 pages · Grade level 9.9 · Accepted 2025-10-08 17:45:26
Key Financial Figures
- $0.00001 — ch registered Common Stock, par value $0.00001 per share AARD The Nasdaq Stock Mar
Filing Documents
- ck0001774857-20251008.htm (8-K) — 45KB
- ck0001774857-ex99_1.htm (EX-99.1) — 28KB
- img213560662_0.jpg (GRAPHIC) — 97KB
- 0001193125-25-234722.txt ( ) — 319KB
- ck0001774857-20251008.xsd (EX-101.SCH) — 25KB
- ck0001774857-20251008_htm.xml (XML) — 5KB
01 Other Events
Item 8.01 Other Events. On October 8, 2025, Aardvark Therapeutics, Inc. (the "Company") issued a press release announcing alignment with the U.S. Food and Drug Administration on a protocol amendment to the Company's Phase 3 HERO trial of ARD-101 for the treatment of hyperphagia associated with Prader-Willi Syndrome. The protocol amendment changes the minimum age of eligibility to participate in the trial from 13 to 10 years old. The full text of the press release is filed as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Press Release, dated October 8, 2025 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. AARDVARK THERAPEUTICS, INC. Date: October 8, 2025 By: /s/ Tien-Li Lee, M.D. Tien-Li Lee, M.D. Chief Executive Officer